Ginsenoside Rg3 induces apoptosis in the U87MG human glioblastoma cell line through the MEK signaling pathway and reactive oxygen species

Oncology Reports

Volumn 30, Issue 3, 2013, Pages 1362-1370

  Choi, Yoon Ji ^a   Lee, Hyun Joo ^b   Kang, Dong Wan ^a   Han, In Ho ^a,b   Choi, Byung Kwan ^a,b   Cho, Won Ho ^a,b  

^a Pusan National University Hospital   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

Author keywords

Apoptosis; Ginsenoside Rg3; MEK signaling; Reactive oxygen species; U87MG cell

Indexed keywords

GINSENOSIDE RG 1; GINSENOSIDE RG 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

AMINO ACID CHLOROMETHYL KETONES; ANTIOXIDANTS; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CASPASES; CELL PROLIFERATION; FLOW CYTOMETRY; GINSENOSIDES; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MAP KINASE KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASES; PANAX; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84880635751     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2555     Document Type: Article

References (59)

1. Chamberlain MC: Treatment options for glioblastoma. Neurosurg Focus 20: E19, 2006.
2. Chamberlain M: Evolving strategies: future treatment of glioblastoma. Expert Rev Neurother 11: 519-532, 2011.
3. Schratter-Sehn AU and Marosi C: Treatment of glioblastoma recurrences. Wien Med Wochenschr 161: 1-2, 2011 (In German).
4. Kala M, Srámek V, Houdek M, Vaverka M and Zmrzlík P: Treatment of glioblastoma multiforme. Cas Lek Cesk 132: 653-656, 1993 (In Czech).
5. Holland EC: Glioblastoma multiforme: the terminator. Proc Natl Acad Sci USA 97: 6242-6244, 2000.
6. Yun TK, Lee YS, Lee YH, Kim SI and Yun HY: Anticarcinogenic effect of Panax ginseng C.A. Meyer and identification of active compounds. J Korean Med Sci 16 (Suppl): S6-S18, 2001.
7. De Souza LR, Jenkins AL, Sievenpiper JL, Jovanovski E, Rahelić D and Vuksan V: Korean red ginseng (Panax ginseng C.A. Meyer) root fractions: differential effects on postprandial glycemia in healthy individuals. J Ethnopharmacol 137: 245-250, 2011.
8. Varjas T, Nowrasteh G, Budán F, et al: Chemopreventive effect of Panax ginseng. Phytother Res 23: 1399-1403, 2009.
9. Helms S: Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev 9: 259-274, 2004.
10. Shin HR, Kim JY, Yun TK, Morgan G and Vainio H: The cancer-preventive potential of Panax ginseng: a review of human and experimental evidence. Cancer Causes Control 11: 565-576, 2000.
11. Attele AS, Wu JA and Yuan CS: Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 58: 1685-1693, 1999.
12. Yun TK: Experimental and epidemiological evidence on non-organ specific cancer preventive effect of Korean ginseng and identification of active compounds. Mutat Res 523-524: 63-74, 2003.
13. Lu P, Su W, Miao ZH, Niu HR, Liu J and Hua QL: Effect and mechanism of ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer. Chin J Integr Med 14: 33-36, 2008.
14. Ji C, Ren F and Xu M: Caspase-8 and p38MAPK in DATS-induced apoptosis of human CNE2 cells. Braz J Med Biol Res 43: 821-827, 2010.
15. Kim HS, Lee EH, Ko SR, Choi KJ, Park JH and Im DS: Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells. Arch Pharm Res 27: 429-435, 2004.
16. Youle RJ and Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59, 2008.
17. Fan TJ, Han LH, Cong RS and Liang J: Caspase family proteases and apoptosis. Acta Biochim Biophys Sin (Shanghai) 37: 719-727, 2005.
18. Olsson M and Zhivotovsky B: Caspases and cancer. Cell Death Differ 18: 1441-1449, 2011.
19. Cohen GM: Caspases: the executioners of apoptosis. Biochem J 326: 1-16, 1997.
20. Raman M, Chen W and Cobb MH: Differential regulation and properties of MAPKs. Oncogene 26: 3100-3112, 2007.
21. Seger R and Krebs EG: The MAPK signaling cascade. FASEB J 9: 726-735, 1995.
22. Roux PP and Blenis J: ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 320-344, 2004.
23. Zohrabian VM, Forzani B, Chau Z, Murali R and Jhanwar-Uniyal M: Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res 29: 119-123, 2009.
24. Fang JY and Richardson BC: The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6: 322-327, 2005.
25. Kolch W: Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351: 289-305, 2000.
26. Circu ML and Aw TY: Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 48: 749-762, 2010.
27. Stadtman ER: Protein oxidation and aging. Science 257: 1220-1224, 1992.
28. Stadtman ER: Role of oxidant species in aging. Curr Med Chem 11: 1105-1112, 2004.
29. Kannan K and Jain SK: Oxidative stress and apoptosis. Pathophysiology 7: 153-163, 2000.
30. Gomes A, Fernandes E and Lima JL: Fluorescence probes used for detection of reactive oxygen species. J Biochem Biophys Methods 65: 45-80, 2005.
31. Yue PY, Wong DY, Wu PK, et al: The angiosuppressive effects of 20(R)- ginsenoside Rg3. Biochem Pharmacol 72: 437-445, 2006.
32. Keum YS, Han SS, Chun KS, et al: Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression, NF-κB activation and tumor promotion. Mutat Res 523-524: 75-85, 2003.
33. Lee JI, Ha YW, Choi TW, et al: Cellular uptake of ginsenosides in Korean white ginseng and red ginseng and their apoptotic activities in human breast cancer cells. Planta Med 77: 133-140, 2011.
34. Christensen LP: Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv Food Nutr Res 55: 1-99, 2009.
35. Xu TM, Cui MH, Xin Y, et al: Inhibitory effect of ginsenoside Rg3 on ovarian cancer metastasis. Chin Med J (Engl) 121: 1394-1397, 2008.
36. Liu TG, Huang Y, Cui DD, et al: Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice. BMC Cancer 9: 250, 2009.
37. Henson JW: Treatment of glioblastoma multiforme: a new standard. Arch Neurol 63: 337-341, 2006.
38. Wong ET and Yamaguchi NH: Treatment advances for glioblastoma. Expert Rev Neurother 11: 1343-1345, 2011.
39. Yue TL, Ohlstein EH and Ruffolo RR Jr: Apoptosis: a potential target for discovering novel therapies for cardiovascular diseases. Curr Opin Chem Biol 3: 474-480, 1999.
40. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11: 121-139, 1992.
41. Kerr JF, Wyllie AH and Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972.
42. Nagata S: DNA degradation in development and programmed cell death. Annu Rev Immunol 23: 853-875, 2005.
43. Wieder R: TUNEL assay as a measure of chemotherapy-induced apoptosis. Methods Mol Med 111: 43-54, 2005.
44. He BC, Gao JL, Luo X, et al: Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/β-catenin signaling. Int J Oncol 38: 437-445, 2011.
45. Jiang JW, Chen XM, Chen XH and Zheng SS: Ginsenoside Rg3 inhibit hepatocellular carcinoma growth via intrinsic apoptotic pathway. World J Gastroenterol 17: 3605-3613, 2011.
46. Yuan HD, Quan HY, Zhang Y, Kim SH and Chung SH: 20(S)-Ginsenoside Rg3-induced apoptosis in HT-29 colon cancer cells is associated with AMPK signaling pathway. Mol Med Rep 3: 825-831, 2010.
47. Dhanasekaran DN and Johnson GL: MAPKs: function, regulation, role in cancer and therapeutic targeting. Oncogene 26: 3097-3099, 2007.
48. Kyriakis JM, App H, Zhang XF, et al: Raf-1 activates MAP kinase-kinase. Nature 358: 417-421, 1992.
49. Mavria G, Vercoulen Y, Yeo M, et al: ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell 9: 33-44, 2006.
50. Allen CL and Bayraktutan U: Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int J Stroke 4: 461-470, 2009.
51. Wiseman H and Halliwell B: Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 313: 17-29, 1996.
52. Bannister JV, Bannister WH and Rotilio G: Aspects of the structure, function, and applications of superoxide dismutase. CRC Crit Rev Biochem 22: 111-180, 1987.
53. Chelikani P, Fita I and Loewen PC: Diversity of structures and properties among catalases. Cell Mol Life Sci 61: 192-208, 2004.
54. Rhee SG, Chae HZ and Kim K: Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 38: 1543-1552, 2005.
55. Oberley TD and Oberley LW: Antioxidant enzyme levels in cancer. Histol Histopathol 12: 525-535, 1997.
56. Kong Q and Lillehei KO: Antioxidant inhibitors for cancer therapy. Med Hypotheses 51: 405-409, 1998.
57. Bechtel W and Bauer G: Catalase protects tumor cells from apoptosis induction by intercellular ROS signaling. Anticancer Res 29: 4541-4557, 2009.
58. Zafarullah M, Li WQ, Sylvester J and Ahmad M: Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 60: 6-20, 2003.
59. Aruoma OI, Halliwell B, Hoey BM and Butler J: The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 6: 593-597, 1989.